Af­ter un­ex­pect­ed tie, Am­s­ter­dam wins 'coin toss' for new EMA HQ

Well, that was un­ex­pect­ed. The EU’s third and fi­nal vote on the new lo­ca­tion of the Eu­ro­pean Med­i­cine Agency tied be­tween Mi­lan and Am­s­ter­dam, with Am­s­ter­dam win­ning the prover­bial coin toss tie-break­er (EU of­fi­cials drew the city’s name out of a bowl).

The re­sults may sur­prise those fol­low­ing the first two vot­ing rounds close­ly, as Mi­lan came in the lead on the pre­vi­ous ses­sions. Both cities ranked ex­tra­or­di­nar­i­ly well on the EMA’s score­card, with the lo­ca­tions es­pe­cial­ly pop­u­lar with the agency’s 900-per­son staff. The EMA said ear­li­er this month that 65% or more of its staff would be will­ing to re­lo­cate to both Mi­lan and Am­s­ter­dam. Ac­cord­ing to a staff sur­vey in Sep­tem­ber, Am­s­ter­dam would woo the most EMA staffers to re­lo­cate, while Mi­lan ranked fourth.

Staffers like­ly breathed a sigh of re­lief that oth­er top-ranked cities like Bratisla­va and Bucharest did not end up in the top three. Less than 30% of staffers were will­ing to move to those cities, which would have put the EMA in a tough po­si­tion — un­der­staffed and on­ly able to work on top pri­or­i­ty ef­forts.

The EMA has called Lon­don home since 1995, when it was first es­tab­lished. From there, it mon­i­tors and ap­proves drugs across 28 Eu­ro­pean Union mem­ber states and 500 mil­lion peo­ple. Fol­low­ing the Unit­ed King­dom’s vote to ex­it the EU in 2019, the EMA has been scram­bling to choose a site that will meet all of its (many) needs. The re­lo­ca­tion caused a fren­zy of bids from ma­jor cities through­out Eu­rope, first to­tal­ing 19 prospec­tive cities but with three drop­ping out ear­ly this morn­ing: Mal­ta, Za­greb, and Dublin.

The EU’s top cri­te­ria for the EMA’s new home city is ac­ces­si­bil­i­ty to in­ter­na­tion­al trav­el and bilin­gual ed­u­ca­tion for the staffer’s chil­dren. The EMA’s staff has been a ma­jor con­cern, as an ex­o­dus of em­ploy­ees would mean a slow down of process­es. The EMA warned last month that, worst-case sce­nario, its re­lo­ca­tion from Lon­don could per­ma­nent­ly dam­age the med­i­cines reg­u­la­to­ry sys­tem, trig­ger­ing a pub­lic health cri­sis.

If it can’t com­pen­sate for large staff loss­es fol­low­ing its re­lo­ca­tion, it would be forced to in­voke its Brex­it pre­pared­ness busi­ness con­ti­nu­ity plan. The plan has the EMA de­creas­ing its ac­tiv­i­ties to on­ly in­clude those with high pri­or­i­ty. Ac­tiv­i­ties such as cor­po­rate gov­er­nance, au­dits and con­fer­ences are list­ed as the low­est pri­or­i­ties. The top pri­or­i­ties in­clude the as­sess­ment and safe­ty mon­i­tor­ing of med­i­cines and ac­tiv­i­ties vi­tal for main­tain­ing the in­fra­struc­ture of the Eu­ro­pean med­i­cines reg­u­la­to­ry net­work.

To con­tin­ue car­ry­ing out its high­ly pri­or­i­tized ac­tiv­i­ties, the EMA says it needs 462 full time equiv­a­lent (FTE) staff — close to 50% of its cur­rent staff. It needs an­oth­er 140 to car­ry out medi­um pri­or­i­ty work and a fur­ther 110 to con­tin­ue to per­form its low­est pri­or­i­ty ac­tiv­i­ties.

Am­s­ter­dam has a num­ber of things go­ing for it, ac­cord­ing to the EMA’s score­card. It has good flight con­nec­tiv­i­ty to oth­er Eu­ro­pean Eco­nom­ic Area cap­i­tal cities and in­ter­na­tion­al lo­ca­tions. It has ex­cel­lent pub­lic trans­port be­tween the air­port and the pro­posed premis­es of the EMA. It al­so has lots of hous­ing and “high qual­i­ty ac­com­mo­da­tion” with­in walk­ing dis­tance to the pro­posed HQ site. And there’s lots of Eu­ro­pean-ori­ent­ed schools.

Mi­lan had many of the same things go­ing for it, ex­cept the city al­so in­clud­ed de­tails on cur­rent and fu­ture school ca­pac­i­ty for the staffer’s chil­dren, which may have eased wor­ry about putting hun­dreds of new stu­dents in­to lo­cal schools.

Now, the EMA has plen­ty on its plate. The agency has to take up new op­er­a­tions at the Am­s­ter­dam site by March 2019. Fit­ting out the new head­quar­ters alone will take 12-15 months, the agency es­ti­mates. Build­ing one in time will re­quire fast ac­tion and a hur­ry-up con­struc­tion sched­ule.

Re­ac­tions

Here’s Steve Bates, CEO of the UK’s BioIn­dus­try As­so­ci­a­tion:

“Lon­don’s loss is Am­s­ter­dam’s gain. To­day’s de­ci­sion on the lo­ca­tion of the Eu­ro­pean Med­i­cines Agency means a 1000 high qual­i­ty jobs leav­ing the UK, dis­rupt­ing a thou­sand fam­i­lies as a di­rect re­sult of Brex­it, with im­pli­ca­tions for thou­sands more. Busi­ness­es now need cer­tain­ty. The best way to do this is by an ear­ly agree­ment to a tran­si­tion time­frame and con­tin­ued close reg­u­la­to­ry co-op­er­a­tion. We must now en­sure Brex­it does not dis­rupt the safe sup­ply of vi­tal med­i­cines to tens of mil­lions of fam­i­lies in the EU 27 and the UK.”


Mar­tine Dehlinger-Kre­mer, VP of Glob­al Med­ical and Reg­u­la­to­ry Af­fairs at in­ter­na­tion­al CRO Syn­ter­ac­tHCR, says Am­s­ter­dam has all the cri­te­ria to be a suc­cess­ful move:

Am­s­ter­dam is a very dy­nam­ic city and an in­ter­na­tion­al­ly ori­ent­ed city. The Nether­lands of­fers all the fa­cil­i­ties nec­es­sary for the agency to re­lo­cate quick­ly and ef­fi­cient­ly. Am­s­ter­dam will be able to pro­vide good hous­ing, in­ter­na­tion­al schools and health­care for the EMA em­ploy­ees as well as ac­cess to the labour mar­ket for their part­ners. Am­s­ter­dam is well recog­nised med­ical and sci­ence in­dus­try. Am­s­ter­dam has even been nom­i­nat­ed as the Eu­ro­pean Cap­i­tal of In­no­va­tion by the Eu­ro­pean Union. Am­s­ter­dam of­fers one of Eu­rope’s biggest air­ports which will al­low easy and fast ac­cess to the EMA vis­i­tors.”


And Pier­lui­gi Parac­chi, CEO of Italy’s Genen­ta:


Im­age: Am­s­ter­dam Shut­ter­stock

The Advance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

Af­ter de­cou­pling from Re­gen­eron, Sanofi says it’s time to sell the $13B stake picked up in the mar­riage

With Regeneron shares going for a peak price — after doubling from last fall — Sanofi is putting a $13 billion stake in their longtime partner on the auction block. And Regeneron is taking $5 billion of that action for themselves.

Sanofi — which has been decoupling from Regeneron for more than a year now — bought in big in early 2013, back when Regeneron’s stock was going for around $165 a share. Small investors flocked to the deal, buzzing about an imminent takeover. The buyout chatter wound down long ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,200+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock, director of the Center for Drug Evaluation and Research (AP Images)

Covid-19 roundup: Hit with new con­flict ac­cu­sa­tions, Janet Wood­cock steps out of the agen­cy's Covid-19 chain of com­mand

Two weeks ago, FDA drug chieftain Janet Woodcock was assuring a top Wall Street analyst that any vaccine approved for combating Covid-19 would have to meet high agency standards on safety and efficacy before it’s approved. But over the weekend, after she and Peter Marks took top positions with the public-private operation meant to speed a new vaccine to lightning-fast approvals — they both recused themselves from the review process after an advocacy group argued their roles close to the White House could pose a conflict of interest.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,200+ biopharma pros reading Endpoints daily — and it's free.

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

Late last year, enthusiasm for Amarin’s fish-oil pill Vascepa burgeoned when the FDA signed off on expanding the cholesterol fighter’s label to include the drug’s beneficial impact on cardiovascular risk, but months later the exuberance for the blockbuster-to-be took a big hit when a judge invalidated key patents protecting Vascepa.

Despite Amarin’s $AMRN pledge to appeal — a process that could take months — the ruling opened the door for generic competition. Hikma Pharmaceuticals, one of three challengers in the Nevada suit, on Friday said that its generic copy of pure EPA, the omega-3 fatty acid that constitutes Vascepa, has been approved by the FDA.

Eric Edwards, Phlow president and CEO (PR Newswire)

BAR­DA of­fers a tiny start­up up to $812M to cre­ate a US-based drug man­u­fac­tur­er — and the CEO comes with a price goug­ing con­tro­ver­sy on his ré­sumé

BARDA has tapped a largely unknown startup to ramp up production of a list of drugs that may be at risk of running short in the US. And the deal, which comes with up to $812 million in federal funds, was inked by a CEO who found himself in the middle of an ugly price gouging controversy a few years ago.

The feds’ new partner — called Phlow — won a 4-year “base” contract of $354 million, with another $458 million that’s on the table in potential options to sustain the outfit. That would make it one of the largest awards in BARDA’s history.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,200+ biopharma pros reading Endpoints daily — and it's free.

Re­searchers de­fine ex­act­ly what they saw in the first pos­i­tive remde­sivir study for Covid-19. But what's that worth to Gilead?

Remdesivir can work in fighting Covid-19, particularly for patients with less severe cases, but this is just a first step in the journey to finding combos that can do the job much better,

That’s the bottom line from Gilead’s randomized study published in the New England Journal of Medicine. Analysts were quick to draw conclusions about how the big biotech could turn this into a profitable advantage — with widespread expectation of considerable pricing restraint on Gilead’s part. Anyone looking for a new mountain of cash to count as the world grapples with the pandemic is likely to come away disappointed.

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

Prostate cancer patients have another PARP inhibitor option in a matter of days.

Clovis’ Rubraca won its prostate cancer approval on Friday, but data from AstraZeneca and Merck rival Lynparza put a damper on commercial expectations. Now, the FDA has approved Lynparza in the prostate cancer setting, months ahead of its expected decision date.

Lynparza has been approved for patients with metastatic castration-resistant prostate cancer (mCRPC), who carry BRCA or ATM mutations, which account for roughly 20-30% of patients with mCRPC. The approval was based on the late-stage PROfound trial, which found the drug eclipsed the impact of the androgen therapies at reducing the risk of disease progression or death by a sharp 66%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,200+ biopharma pros reading Endpoints daily — and it's free.

An­oth­er NASH de­lay for In­ter­cept frus­trates in­vestors, shares wilt

A previous FDA advisory committee delay for Intercept’s NASH drug may have dampened spirits, but investors perked up after French rival Genfit recently failed to best a placebo with its offering in a keenly anticipated pivotal study. In yet another twist on Friday, the New York drugmaker said the FDA is postponing its adcom again to accommodate the review of additional data it has asked the company to furnish.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,200+ biopharma pros reading Endpoints daily — and it's free.

Photo credit: Shutterstock

Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

Before Merck and Merck, there was only Merck.

A single company was founded as a drugmaker in the pre-Bismarckian days of an industrializing Germany that, in 1891, decided to launch an outpost in New York. It was a successful idea, launching a smallpox vaccine just 7 years later, until World War I, when the US government seized the US branch under the Trading with the Enemy Act, splitting the global corporation in two and setting off a century of intercontinental brand confusion.